Biotechnology firm Biocon Ltd on Thursday (March 6) said its arm Biocon Biologics Ltd has entered into a strategic collaboration with Civica Inc, a not-for-profit pharmaceutical company, to enhance the accessibility and affordability of insulin aspart in the United States.
Civica, founded in 2018, focuses on addressing life-saving drug shortages and reducing costs for essential medications. Through this partnership, Biocon Biologics aims to support broader insulin availability, ensuring more patients have access to affordable diabetes treatment.
Under the terms of the agreement, Biocon Biologics will supply the insulin aspart drug substance to Civica, which will then use to produce the insulin aspart drug product, a rapid-acting insulin analog, at its manufacturing facility in Petersburg, Virginia.
Also Read: Biocon gets FDA nod for cancer drugs lenalidomide and dasatinib
Civica will commercialise the medicine for patients in the United States after the completion of development work and clinical trials. No technology transfer is involved in the agreement.
Shreehas Tambe, CEO and Managing Director of Biocon Biologics, said, “As a fully integrated global biologics company, Biocon Biologics is uniquely positioned to drive commercial success through tailored go-to-market strategies that create lasting value for all stakeholders.
Our collaboration with Civica reflects this commitment, enabling us to expand patient access to insulin aspart in the United States while reinforcing our dedication to serving the growing needs of people living with diabetes.”
Also Read: Biocon targets mid-teen revenue growth with new product pipeline
This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the United States, which is currently under US Food and Drug Administration (FDA) review.
Shares of Biocon Ltd ended at ₹333.10, up by ₹8.45, or 2.60%, on the BSE.
(Edited by : Shoma Bhattacharjee)
First Published: Mar 6, 2025 7:18 PM IST
